There are reports of policy shifts related to diversity, equity, and inclusion (dei) in clinical trials. The impact of these shifts on the biotech and medical device industries is being discussed, with some outlets offering guidance on navigating the changes. However, the specific details and scope of the policy shifts are not clearly defined across the various reports.